



CORRECTION

Author Correction: Discovery of toxoflavin, a potent IRE1 α inhibitor acting through structure-dependent oxidative inhibition

Kai-long Jiang^{1,2,3,4,5}, Chang-mei Liu^{3,6}, Li-tong Nie³, Hai-ni Jiang^{2,7}, Lei Xu^{2,3}, Kun-zhi Zhang^{3,8}, Li-xia Fan³, An-hui Gao³, Lu-lin Lin¹, Xiang-yu Wang⁵, Min-jia Tan³, Qi-qing Zhang¹✉, Yu-bo Zhou^{2,3,4}✉ and Jia Li^{2,3,4,7,9}✉

Acta Pharmacologica Sinica (2023) 0:1; <https://doi.org/10.1038/s41401-023-01132-4>

Correction to: *Acta Pharmacologica Sinica* <https://doi.org/10.1038/s41401-022-00949-9>, published online 15 July 2022

The authors are very sorry for two mistakes in the spelling of two authors' names among the listed co-authors: The 9th author "Lu-ling Lin" and 11th author "Ming-jia Tan" were spelled incorrectly,

and the correct spelling should be "Lu-lin Lin" and "Min-jia Tan". These errors were made completely by accident, due to our negligence. The authors apologize for any inconvenience caused to the Journal and readers.

¹Institute of Biomedical Engineering, The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen 518020, China; ²Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China; ³State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; ⁴University of Chinese Academy of Sciences, Beijing 100049, China; ⁵The First Affiliated Hospital, Jinan University, Guangzhou 510632, China; ⁶School of Pharmaceutical Science, Jiangnan University, Wuxi 214122, China; ⁷School of Pharmacy, Zunyi Medical University, Zunyi 563006, China; ⁸Zhejiang Center for Medical Device Evaluation, Zhejiang Medical Products Administration, Hangzhou 311121, China and ⁹Shanghai Tech University, Shanghai 201210, China
Correspondence: Qi-qing Zhang (zhang.qiqing@szhospital.com) or Yu-bo Zhou (ybzhou@simm.ac.cn) or Jia Li (jli@simm.ac.cn)